These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2856782)

  • 1. The significance of calcium and calcium channel blockade in essential hypertension.
    Resnick LM; Laragh JH
    J Hypertens Suppl; 1985 Dec; 3(3):S541-4. PubMed ID: 2856782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium metabolism in essential hypertension: relationship to altered renin system activity.
    Resnick LM; Nicholson JP; Laragh JH
    Fed Proc; 1986 Nov; 45(12):2739-45. PubMed ID: 3533639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium antagonists as a new treatment modality in hypertension.
    Laragh JH
    Angiology; 1988 Jan; 39(1 Pt 2):100-5. PubMed ID: 3277491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of sodium and calcium in clinical hypertension: mediating role of vitamin D metabolism.
    Resnick LM
    Adv Second Messenger Phosphoprotein Res; 1990; 24():535-41. PubMed ID: 2119657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium metabolism, renin activity, and the antihypertensive effects of calcium channel blockade.
    Resnick L
    Am J Med; 1986 Dec; 81(6A):6-14. PubMed ID: 2432779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin, calcium metabolism and the pathophysiologic basis of antihypertensive therapy.
    Resnick LM; Laragh JH
    Am J Cardiol; 1985 Dec; 56(16):68H-74H. PubMed ID: 2866707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognizing and treating two types of long-term vasoconstriction in hypertension.
    Laragh JH; Resnick LM
    Kidney Int Suppl; 1988 Sep; 25():S162-74. PubMed ID: 3054233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium metabolism and the renin-aldosterone system in essential hypertension.
    Resnick LM; Nicholson JP; Laragh JH
    J Cardiovasc Pharmacol; 1985; 7 Suppl 6():S187-93. PubMed ID: 2414586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical aspects of parathyroid hypertensive factor.
    Lewanczuk RZ; Resnick LM; Ho MS; Benishin CG; Shan J; Pang PK
    J Hypertens Suppl; 1994 Jan; 12(1):S11-6. PubMed ID: 8207559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divalent cations in essential hypertension. Relations between serum ionized calcium, magnesium, and plasma renin activity.
    Resnick LM; Laragh JH; Sealey JE; Alderman MH
    N Engl J Med; 1983 Oct; 309(15):888-91. PubMed ID: 6350880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular ionic consequences of dietary salt loading in essential hypertension. Relation to blood pressure and effects of calcium channel blockade.
    Resnick LM; Gupta RK; DiFabio B; Barbagallo M; Mann S; Marion R; Laragh JH
    J Clin Invest; 1994 Sep; 94(3):1269-76. PubMed ID: 8083368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute antihypertensive and hormonal effects of a calcium antagonist in essential hypertension.
    Thibonnier M; Corvol P; Banzet O; Menard J
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S335-9. PubMed ID: 6184564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
    Weir MR
    J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologic rationale for calcium antagonist therapy in essential hypertension.
    Resnick LM
    Ethn Dis; 1998; 8(1):111-9. PubMed ID: 9595255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of altered dietary calcium intake in experimental hypertension: role of intracellular free magnesium.
    Resnick LM; Gupta RK; Sosa RE; Corbett ML; Sealey JE; Laragh JH
    J Hypertens Suppl; 1986 Dec; 4(5):S182-5. PubMed ID: 3553472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium metabolism in the pathophysiology and treatment of clinical hypertension.
    Resnick LM
    Am J Hypertens; 1989 Jun; 2(6 Pt 2):179S-185S. PubMed ID: 2665789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical aspects of parathyroid hypertensive factor.
    Lewanczuk RZ; Benishin CG; Shan J; Pang PK
    J Cardiovasc Pharmacol; 1994; 23 Suppl 2():S23-6. PubMed ID: 7518541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-course of changes in intracellular cations and blood pressure with salt loading in patients with essential hypertension.
    Kainouchi M; Matsuura H; Shingu T; Inoue I; Ishida T; Ozono R; Fujii T; Yuasa A; Oshima T; Kajiyama G
    J Hypertens Suppl; 1991 Dec; 9(6):S302-3. PubMed ID: 1818978
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease.
    Mizuno Y; Jacob RF; Mason RP
    Am J Hypertens; 2008 Oct; 21(10):1076-85. PubMed ID: 18756260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of dietary calcium intake as a therapeutic modality in essential hypertension.
    Resnick LM
    Can J Physiol Pharmacol; 1986 Jun; 64(6):803-7. PubMed ID: 3530409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.